Dallas, TX (PRWEB) September 25, 2012
China's demand for drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow for drugs targeted at multiple diseases including but not limited to Cardiovascular, Treatment of Arthritis, Asthma, Leukemia, Tuberculosis, Kidney Cancer, Skin Cancer, Digestive Remedies, Anti-infectious Disease, Pain and Fever Relief. New China drugs market research reports by AMID examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants for each of these segments. Major producers of these drugs in China are profiled in concerned reports.
Place your order before December 31, 2012 to avail a special discount of 50% on all reports by AMID including the research on Chinese Drug Markets @ http://www.reportsnreports.com/publisher/amid/.
In comparison with major diseases, the targeting of rare diseases poses many different challenges, necessitating consideration of bespoke R&D strategies for drug discovery efforts to be successful. This report on Drug Discovery in Rare Diseases examines the role that low disease prevalence plays in determining the most suitable R&D path.
Features and benefits
- Understand the growing interest in developing new treatments for rare diseases, and why low patient numbers do not preclude commercial viability.
- Review the regulatory environment governing the development of orphan drugs in different countries.
- Identify the key challenges that are presented by low patient prevalences.
- Assess how the research strategy chosen can be influenced by the disease prevalence.
- Compare the scenarios in which repurposing of existing drugs offers advantages over the development of novel drugs, and vice versa.
Approximately 7,000 rare diseases have been identified, but only a very small proportion of these are currently well treated. Orphans represent a greater proportion of all new BLAs than they do of NMEs submitted as NDAs. Most orphan approvals are not first approvals of new drugs but are new orphan indications for previously approved drugs.
It is possible to obtain orphan drug designation for conditions with a total prevalence greater than that defined by legislation, but only if medically justifiable subsets can be defined with a lower (overall) prevalence. Pediatric subsets are most commonly used.
In the development of new treatments for rare diseases it is less critical to seek to optimize the pharmacokinetic properties of candidates than is the case for common chronic diseases, with parenteral delivery or frequent oral dosing being much more acceptable provided that efficacy is achieved.
Your key questions answered
- What impact on R&D strategy does disease prevalence have on moving from rare through very rare to ultra rare diseases?
- Can more than one drug be a commercial success for treating rare indications, and how do drug regulators view the question of drug similarity?
- What are the best ways of identifying patients for recruitment into clinical trials for drugs designed to treat rare diseases?
- What are the requirements for a clinical candidate to treat a rare disease?
- What factors determine whether a small-molecule or biologic strategy is most suitable when targeting a rare disease?
Buy your copy of this report @ http://www.reportsnreports.com/reports/192270-drug-discovery-in-rare-diseases.html.
Browse special reports available on Discount for limited period @ http://www.reportsnreports.com/discount_reports.aspx.
Contact sales(at)reportsandreports(dot)com for further information.
ReportsnReports.com is an online market research reports library of 200,000+ in-depth studies of 5000+ micro markets. We provide 24/7 online and offline support service to our customers.